List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/398667/publications.pdf Version: 2024-02-01



FDEVALLEOWKES

#	Article	IF	CITATIONS
1	Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis. The Lancet Global Health, 2019, 7, e1020-e1030.	6.3	662
2	Peripheral artery disease: epidemiology and global perspectives. Nature Reviews Cardiology, 2017, 14, 156-170.	13.7	470
3	The Relationship between Anti-merozoite Antibodies and Incidence of Plasmodium falciparum Malaria: A Systematic Review and Meta-analysis. PLoS Medicine, 2010, 7, e1000218.	8.4	306
4	Merozoite surface proteins in red blood cell invasion, immunity and vaccines against malaria. FEMS Microbiology Reviews, 2016, 40, 343-372.	8.6	275
5	Revealing the Sequence and Resulting Cellular Morphology of Receptor-Ligand Interactions during Plasmodium falciparum Invasion of Erythrocytes. PLoS Pathogens, 2015, 11, e1004670.	4.7	246
6	Inhibition of placental mTOR signaling provides a link between placental malaria and reduced birthweight. BMC Medicine, 2017, 15, 1.	5.5	242
7	ldentification and Prioritization of Merozoite Antigens as Targets of Protective Human Immunity to <i>Plasmodium falciparum</i> Malaria for Vaccine and Biomarker Development. Journal of Immunology, 2013, 191, 795-809.	0.8	213
8	Targets of antibodies against Plasmodium falciparum–infected erythrocytes in malaria immunity. Journal of Clinical Investigation, 2012, 122, 3227-3238.	8.2	187
9	Association between Naturally Acquired Antibodies to Erythrocyteâ€Binding Antigens of <i>Plasmodium falciparum</i> and Protection from Malaria and Highâ€Density Parasitemia. Clinical Infectious Diseases, 2010, 51, e50-e60.	5.8	184
10	Host erythrocyte polymorphisms and exposure to Plasmodium falciparum in Papua New Guinea. Malaria Journal, 2008, 7, 1.	2.3	161
11	Surface antigens of Plasmodium falciparum-infected erythrocytes as immune targets and malaria vaccine candidates. Cellular and Molecular Life Sciences, 2014, 71, 3633-3657.	5.4	131
12	Acquisition of Antibodies against Plasmodium falciparum Merozoites and Malaria Immunity in Young Children and the Influence of Age, Force of Infection, and Magnitude of Response. Infection and Immunity, 2015, 83, 646-660.	2.2	121
13	Quantification of the association between malaria in pregnancy and stillbirth: a systematic review and meta-analysis. The Lancet Global Health, 2017, 5, e1101-e1112.	6.3	102
14	Malaria eradication and elimination: views on how to translate a vision into reality. BMC Medicine, 2015, 13, 167.	5.5	101
15	A Phase 1 Trial of MSP2-C1, a Blood-Stage Malaria Vaccine Containing 2 Isoforms of MSP2 Formulated with Montanide® ISA 720. PLoS ONE, 2011, 6, e24413.	2.5	88
16	Acquisition of Growth-Inhibitory Antibodies against Blood-Stage Plasmodium falciparum. PLoS ONE, 2008, 3, e3571.	2.5	88
17	New Insights into Acquisition, Boosting, and Longevity of Immunity to Malaria in Pregnant Women. Journal of Infectious Diseases, 2012, 206, 1612-1621.	4.0	85
18	Evidence That the Erythrocyte Invasion Ligand PfRh2 is a Target of Protective Immunity against <i>Plasmodium falciparum</i> Malaria. Journal of Immunology, 2010, 185, 6157-6167.	0.8	84

#	Article	IF	CITATIONS
19	Human antibodies activate complement against Plasmodium falciparum sporozoites, and are associated with protection against malaria in children. BMC Medicine, 2018, 16, 61.	5.5	79
20	The Stability and Complexity of Antibody Responses to the Major Surface Antigen of Plasmodium falciparum Are Associated with Age in a Malaria Endemic Area. Molecular and Cellular Proteomics, 2011, 10, M111.008326.	3.8	78
21	Host immunity to <i>Plasmodium falciparum</i> and the assessment of emerging artemisinin resistance in a multinational cohort. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 3515-3520.	7.1	78
22	Targets of complement-fixing antibodies in protective immunity against malaria in children. Nature Communications, 2019, 10, 610.	12.8	76
23	Bacterial Vaginosis (BV) Candidate Bacteria: Associations with BV and Behavioural Practices in Sexually-Experienced and Inexperienced Women. PLoS ONE, 2012, 7, e30633.	2.5	69
24	Safety of artemisinins in first trimester of prospectively followed pregnancies: an observational study. Lancet Infectious Diseases, The, 2016, 16, 576-583.	9.1	67
25	Immunological markers of Plasmodium vivaxexposure and immunity: a systematic review and meta-analysis. BMC Medicine, 2014, 12, 150.	5.5	66
26	Immunity to malaria in an era of declining malaria transmission. Parasitology, 2016, 143, 139-153.	1.5	66
27	Induction and decay of functional complement-fixing antibodies by the RTS,S malariaÂvaccine in children, and a negative impact of malaria exposure. BMC Medicine, 2019, 17, 45.	5.5	65
28	Erythrocyte-Binding Antigens of <i>Plasmodium falciparum</i> Are Targets of Human Inhibitory Antibodies and Function To Evade Naturally Acquired Immunity. Journal of Immunology, 2013, 191, 785-794.	0.8	62
29	Influence of the number and timing of malaria episodes during pregnancy on prematurity and small-for-gestational-age in an area of low transmission. BMC Medicine, 2017, 15, 117.	5.5	62
30	Bypass surgery for chronic lower limb ischaemia. , 2008, , CD002000.		60
31	The association between naturally acquired IgG subclass specific antibodies to the PfRH5 invasion complex and protection from Plasmodium falciparum malaria. Scientific Reports, 2016, 6, 33094.	3.3	59
32	Research priorities for the development and implementation of serological tools for malaria surveillance. F1000prime Reports, 2014, 6, 100.	5.9	56
33	Increased Microerythrocyte Count in Homozygous α+-Thalassaemia Contributes to Protection against Severe Malarial Anaemia. PLoS Medicine, 2008, 5, e56.	8.4	55
34	Evaluation of the Antigenic Diversity of Placenta-Binding <i>Plasmodium falciparum</i> Variants and the Antibody Repertoire among Pregnant Women. Infection and Immunity, 2010, 78, 1963-1978.	2.2	51
35	The Plasmodium falciparum Erythrocyte Invasion Ligand Pfrh4 as a Target of Functional and Protective Human Antibodies against Malaria. PLoS ONE, 2012, 7, e45253.	2.5	51
36	Quantifying the Importance of MSP1-19 as a Target of Growth-Inhibitory and Protective Antibodies against Plasmodium falciparum in Humans. PLoS ONE, 2011, 6, e27705.	2.5	49

#	Article	IF	CITATIONS
37	Scottish smokeâ€free legislation and trends in smoking cessation. Addiction, 2008, 103, 1888-1895.	3.3	48
38	Pregnancy-specific malarial immunity and risk of malaria in pregnancy and adverse birth outcomes: a systematic review. BMC Medicine, 2020, 18, 14.	5.5	48
39	Mediation of the effect of malaria in pregnancy on stillbirth and neonatal death in an area of low transmission: observational data analysis. BMC Medicine, 2017, 15, 98.	5.5	43
40	Investigating the Efficacy of Triple Artemisinin-Based Combination Therapies for Treating Plasmodium falciparum Malaria Patients Using Mathematical Modeling. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	43
41	Differing rates of antibody acquisition to merozoite antigens in malaria: implications for immunity and surveillance. Journal of Leukocyte Biology, 2017, 101, 913-925.	3.3	41
42	Ozonide Antimalarial Activity in the Context of Artemisinin-Resistant Malaria. Trends in Parasitology, 2019, 35, 529-543.	3.3	40
43	Trying to remember: immunological B cell memory to malaria. Trends in Parasitology, 2015, 31, 89-94.	3.3	38
44	Multifunctional Antibodies Are Induced by the RTS,S Malaria Vaccine and Associated With Protection in a Phase 1/2a Trial. Journal of Infectious Diseases, 2021, 224, 1128-1138.	4.0	38
45	Estimating Gestational Age in Late Presenters to Antenatal Care in a Resource-Limited Setting on the Thai-Myanmar Border. PLoS ONE, 2015, 10, e0131025.	2.5	36
46	Antibodies to Chondroitin Sulfate A–Binding Infected Erythrocytes: Dynamics and Protection during Pregnancy in Women Receiving Intermittent Preventive Treatment. Journal of Infectious Diseases, 2010, 201, 1316-1325.	4.0	35
47	LOW PREVALENCE OF AN ACUTE PHASE RESPONSE IN ASYMPTOMATIC CHILDREN FROM A MALARIA-ENDEMIC AREA OF PAPUA NEW GUINEA. American Journal of Tropical Medicine and Hygiene, 2007, 76, 280-284.	1.4	35
48	HAPTOGLOBIN LEVELS ARE ASSOCIATED WITH HAPTOGLOBIN GENOTYPE AND α+-THALASSEMIA IN A MALARIA-ENDEMIC AREA. American Journal of Tropical Medicine and Hygiene, 2006, 74, 965-971.	1.4	33
49	Declining Malaria Transmission Differentially Impacts the Maintenance of Humoral Immunity to Plasmodium falciparum in Children. Journal of Infectious Diseases, 2017, 216, 887-898.	4.0	31
50	ASSOCIATION OF HAPTOGLOBIN LEVELS WITH AGE, PARASITE DENSITY, AND HAPTOGLOBIN GENOTYPE IN A MALARIA-ENDEMIC AREA OF GABON. American Journal of Tropical Medicine and Hygiene, 2006, 74, 26-30.	1.4	30
51	The impact of community-delivered models of malaria control and elimination: a systematic review. Malaria Journal, 2019, 18, 269.	2.3	28
52	Antibody Targets on the Surface of <i>Plasmodium falciparum–</i> Infected Erythrocytes That Are Associated With Immunity to Severe Malaria in Young Children. Journal of Infectious Diseases, 2019, 219, 819-828.	4.0	28
53	Implications of population-level immunity for the emergence of artemisinin-resistant malaria: a mathematical model. Malaria Journal, 2018, 17, 279.	2.3	26
54	The acute phase response in children with mild and severe malaria in Papua New Guinea. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2009, 103, 679-686.	1.8	25

#	Article	IF	CITATIONS
55	Achieving development goals for HIV, tuberculosis and malaria in sub-Saharan Africa through integrated antenatal care: barriers and challenges. BMC Medicine, 2016, 14, 202.	5.5	23
56	Differences in PfEMP1s recognized by antibodies from patients with uncomplicated or severe malaria. Malaria Journal, 2016, 15, 258.	2.3	23
57	Iron deficiency during pregnancy is associated with a reduced risk of adverse birth outcomes in a malaria-endemic area in a longitudinal cohort study. BMC Medicine, 2018, 16, 156.	5.5	22
58	Haptoglobin levels are associated with haptoglobin genotype and alpha+ -Thalassemia in a malaria-endemic area. American Journal of Tropical Medicine and Hygiene, 2006, 74, 965-71.	1.4	22
59	Patterns of protective associations differ for antibodies to <i>P. falciparum</i> â€infected erythrocytes and merozoites in immunity against malaria in children. European Journal of Immunology, 2017, 47, 2124-2136.	2.9	21
60	Contribution of Functional Antimalarial Immunity to Measures of Parasite Clearance in Therapeutic Efficacy Studies of Artemisinin Derivatives. Journal of Infectious Diseases, 2019, 220, 1178-1187.	4.0	21
61	A single point in protein trafficking by Plasmodium falciparum determines the expression of major antigens on the surface of infected erythrocytes targeted by human antibodies. Cellular and Molecular Life Sciences, 2016, 73, 4141-4158.	5.4	20
62	Anopheles Salivary Biomarker as a Proxy for Estimating Plasmodium falciparum Malaria Exposure on the Thailand–Myanmar Border. American Journal of Tropical Medicine and Hygiene, 2018, 99, 350-356.	1.4	19
63	Association of haptoglobin levels with age, parasite density, and haptoglobin genotype in a malaria-endemic area of Gabon. American Journal of Tropical Medicine and Hygiene, 2006, 74, 26-30.	1.4	19
64	PfEMP1 as a target of human immunity and a vaccine candidate against malaria. Expert Review of Vaccines, 2013, 12, 105-108.	4.4	17
65	P. falciparum infection and maternofetal antibody transfer in malaria-endemic settings of varying transmission. PLoS ONE, 2017, 12, e0186577.	2.5	17
66	Evaluation of the effectiveness of topical repellent distributed by village health volunteer networks againstÂPlasmodium spp. infection in Myanmar: AÂstepped-wedge cluster randomised trial. PLoS Medicine, 2020, 17, e1003177.	8.4	16
67	Epistatic Interactions between Apolipoprotein E and Hemoglobin S Genes in Regulation of Malaria Parasitemia. PLoS ONE, 2013, 8, e76924.	2.5	15
68	The impact of lipid-based nutrient supplementation on anti-malarial antibodies in pregnant women in a randomized controlled trial. Malaria Journal, 2015, 14, 193.	2.3	15
69	Declining Transmission and Immunity to Malaria and Emerging Artemisinin Resistance in Thailand: A Longitudinal Study. Journal of Infectious Diseases, 2017, 216, 723-731.	4.0	15
70	Induction and Kinetics of Complement-Fixing Antibodies Against Plasmodium vivax Merozoite Surface Protein 31± and Relationship With Immunoglobulin G Subclasses and Immunoglobulin M. Journal of Infectious Diseases, 2019, 220, 1950-1961.	4.0	15
71	Plasmodium vivax Malaria. Pediatric Infectious Disease Journal, 2015, 34, 529-531.	2.0	14
72	Recent insights into humoral immunity targeting Plasmodium falciparum and Plasmodium vivax malaria. International Journal for Parasitology, 2017, 47, 99-104.	3.1	14

#	Article	IF	CITATIONS
73	Implications of the licensure of a partially efficacious malaria vaccine on evaluating second-generation vaccines. BMC Medicine, 2013, 11, 232.	5.5	13
74	Water, Sanitation, and Hygiene Facilities and Hygiene Practices Associated with Diarrhea and Vomiting in Monastic Schools, Myanmar. American Journal of Tropical Medicine and Hygiene, 2016, 95, 278-287.	1.4	13
75	Maternal-foetal transfer of Plasmodium falciparum and Plasmodium vivax antibodies in a low transmission setting. Scientific Reports, 2016, 6, 20859.	3.3	13
76	Immunity as a predictor of anti-malarial treatment failure: a systematic review. Malaria Journal, 2017, 16, 158.	2.3	13
77	Use of Immunodampening To Overcome Diversity in the Malarial Vaccine Candidate Apical Membrane Antigen 1. Infection and Immunity, 2014, 82, 4707-4717.	2.2	10
78	Effectiveness of repellent delivered through village health volunteers on malaria incidence in villages in South-East Myanmar: a stepped-wedge cluster-randomised controlled trial protocol. BMC Infectious Diseases, 2018, 18, 663.	2.9	10
79	Reduced risk of placental parasitemia associated with complement fixation on Plasmodium falciparum by antibodies among pregnant women. BMC Medicine, 2021, 19, 201.	5.5	10
80	A Dynamic Stress Model Explains the Delayed Drug Effect in Artemisinin Treatment of Plasmodium falciparum. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	9
81	A mobile phone application for malaria case-based reporting to advance malaria surveillance in Myanmar: a mixed methods evaluation. Malaria Journal, 2021, 20, 167.	2.3	9
82	Maximizing antimalarial efficacy and the importance of dosing strategies. BMC Medicine, 2015, 13, 110.	5.5	8
83	Association between malaria immunity and pregnancy outcomes among Malawian pregnant women receiving nutrient supplementation. Malaria Journal, 2016, 15, 547.	2.3	8
84	Can malaria parasites be spontaneously cleared?. Trends in Parasitology, 2022, 38, 356-364.	3.3	8
85	Individual Variation in Levels of Haptoglobin-Related Protein in Children from Gabon. PLoS ONE, 2012, 7, e49816.	2.5	7
86	Quantification of the dynamics of antibody response to malaria to inform sero-surveillance in pregnant women. Malaria Journal, 2022, 21, 75.	2.3	7
87	Anopheles salivary antigens as serological biomarkers of vector exposure and malaria transmission: A systematic review with multilevel modelling. ELife, 2021, 10, .	6.0	7
88	Antibody Boosting and Longevity Following Tetanus Immunization During Pregnancy. Clinical Infectious Diseases, 2013, 56, 749-750.	5.8	6
89	Antibody responses to Plasmodium falciparum and Plasmodium vivax blood-stage and sporozoite antigens in the postpartum period. Scientific Reports, 2016, 6, 32159.	3.3	6
90	Community demand for comprehensive primary health care from malaria volunteers in South-East Myanmar: a qualitative study. Malaria Journal, 2021, 20, 19.	2.3	6

#	Article	IF	CITATIONS
91	Optimizing Myanmar's community-delivered malaria volunteer model: a qualitative study of stakeholders' perspectives. Malaria Journal, 2021, 20, 79.	2.3	6
92	Community-based molecular and serological surveillance of subclinical malaria in Myanmar. BMC Medicine, 2021, 19, 121.	5.5	6
93	Intermittent Preventive Treatment to Reduce the Burden of Malaria in Children: New Evidence on Integration and Delivery. PLoS Medicine, 2011, 8, e1000410.	8.4	5
94	Understanding the interactions between iron supplementation, infectious disease and adverse birth outcomes is essential to guide public health recommendations. BMC Medicine, 2019, 17, 153.	5.5	5
95	The invisible burden of malaria-attributable stillbirths. Lancet, The, 2020, 395, 268.	13.7	5
96	<i>In Silico</i> Investigation of the Decline in Clinical Efficacy of Artemisinin Combination Therapies Due to Increasing Artemisinin and Partner Drug Resistance. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	4
97	The role of naturally acquired antimalarial antibodies in subclinical <i>Plasmodium</i> spp. infection. Journal of Leukocyte Biology, 2022, 111, 1097-1105.	3.3	4
98	The Global Epidemiological Transition in Cardiovascular Diseases: Unrecognised Impact of Endemic Infections on Peripheral Artery Disease. Journal of Epidemiology and Global Health, 2022, 12, 219-223.	2.9	4
99	High Antibodies to VAR2CSA in Response to Malaria Infection Are Associated With Improved Birthweight in a Longitudinal Study of Pregnant Women. Frontiers in Immunology, 2021, 12, 644563.	4.8	3
100	Sustainability of a mobile phone application-based data reporting system in Myanmar's malaria elimination program: a qualitative study. BMC Medical Informatics and Decision Making, 2021, 21, 285.	3.0	2
101	Quantifying Malaria Dynamics Within the Host. Science, 2011, 333, 943-944.	12.6	1
102	Development and Validation of an <i>In Silico</i> Decision Tool To Guide Optimization of Intravenous Artesunate Dosing Regimens for Severe Falciparum Malaria Patients. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	1
103	Antibody Responses to Plasmodium falciparum and Plasmodium vivax and Prospective Risk of Plasmodium spp. Infection Postpartum. American Journal of Tropical Medicine and Hygiene, 2017, 96, 1197-1204.	1.4	1
104	Anti-Gametocyte Antigen Humoral Immunity and Gametocytemia During Treatment of Uncomplicated Falciparum Malaria: A Multi-National Study. Frontiers in Cellular and Infection Microbiology, 2022, 12, 804470.	3.9	1
105	Comparison of antibody responses and parasite clearance in artemisinin therapeutic efficacy studies in Democratic Republic of Congo and Asia. Journal of Infectious Diseases, 0, , .	4.0	1
106	Reply to Eisenhut. Journal of Infectious Diseases, 2013, 208, 705-706.	4.0	0
107	Presenting parasitological data: the good, the bad and the error bar. Parasitology, 2015, 142, 1351-1363.	1.5	0
108	A malaria vaccine in children with HIV. Lancet Infectious Diseases, The, 2016, 16, 1087-1089.	9.1	0

#	Article	IF	CITATIONS
109	Evaluation of the effectiveness and cost effectiveness of a Community-delivered Integrated Malaria Elimination (CIME) model in Myanmar: protocol for an open stepped-wedge cluster-randomised controlled trial. BMJ Open, 2021, 11, e050400.	1.9	о
110	Perspectives of health and community stakeholders on community-delivered models of malaria elimination in Lao People's Democratic Republic: A qualitative study. PLoS ONE, 2022, 17, e0264399.	2.5	0